Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Jeremy Turk: Sleep Disorders in Children and Adolescents with Developmental Disabilities and their Managements


Published on


Published in: Services
  • Be the first to comment

  • Be the first to like this

Jeremy Turk: Sleep Disorders in Children and Adolescents with Developmental Disabilities and their Managements

  1. 1. Knowledge Database • Slide Presentation for the lecture of: Jeremy Turk South London & Maudsley NHS Foundation Trust, UK • Topic of lecture: Sleep Disorders in Children and Adolescents with Developmental Disabilities and their Managements • The lecture was given at Beit Issie Shapiro’s 6th International Conference on Disabilities - Israel • Year: 2015
  2. 2. Sleep Disorders in Children & YoungSleep Disorders in Children & Young People with DevelopmentalPeople with Developmental DisabilitiesDisabilities Jeremy TurkJeremy Turk Academic Child & Adolescent Mental Health,Academic Child & Adolescent Mental Health, Institute of Psychiatry, King’s College, University of LondonInstitute of Psychiatry, King’s College, University of London && Child & Adolescent Mental Health Neurodevelopmental Services,Child & Adolescent Mental Health Neurodevelopmental Services, South London & Maudsley Mental Health Foundation NHS TrustSouth London & Maudsley Mental Health Foundation NHS Trust
  3. 3. Turk, J. (2010)Turk, J. (2010) Sleep Disorders in Children & AdolescentsSleep Disorders in Children & Adolescents with Learning Disabilities & Theirwith Learning Disabilities & Their ManagementsManagements Advances in Mental Health & LearningAdvances in Mental Health & Learning DisabilitiesDisabilities Volume 4, Issue 1,Volume 4, Issue 1, pp. 50-59.pp. 50-59.
  4. 4. Turk, J. (2014) Use of Medication in Children & Young People with Intellectual Disability & Challenging Behaviours “Intellectual Disabilities & Challenging Behaviour” ACAMH Occasional Papers No. 32 (eds: Lovell, M. & Udwin, O.) London: Association for Child & Adolescent Mental Health pp. 36-44.
  5. 5. Common Sleep DifficultiesCommon Sleep Difficulties Insomnia Settling difficulties Recurrent night time waking Early morning waking Nightmares, night terrors, sleep talking, sleep walking, sleep reversal, sleep paralysis
  6. 6. Sleep disorders in childhoodSleep disorders in childhood  15-20%, Isle of Wight study  May be – Settling difficulties (“sleep induction”) – Repeated night-time waking – Early morning waking – Parasomnias e.g. sleep walking, night terrors  Strong association with – daytime behavioural difficulties – maternal stress & depression – Family discord & parental separation – Poor educational attainments & socialisation
  7. 7. QUINE 1991:QUINE 1991: Longitudinal study of sleep disturbance in 200 young people with moderate-to-profound intellectual disability 51% settling problems 67% waking problems 32% of parents reported rarely getting enough sleep
  8. 8. Sleep & Autism Spectrum Conditions:Sleep & Autism Spectrum Conditions: 44-83% sleep disturbance Subjective & objective difficulties - Falling asleep - Staying Biochemical & genetic associations - Low plasma & saliva melatonin levels ? Low melatonin CNS receptor sensitivity ? Lack of circadian secretion rhythm
  9. 9. Behavioural TechniquesBehavioural Techniques Extinction Positive reinforcement +/- fading Shaping & graded approaches Antecedent contingencies Discriminant Learning Regular, structured, predictable & calming bedtime routine
  10. 10. Sleep determinants:Sleep determinants: Primarily social in people with average intellectual abilities – “zeitgebers” Strong neurological components in children and young people with developmental disabilities
  11. 11. MelatoninMelatonin (Turk, 2003; Turk, 2010)(Turk, 2003; Turk, 2010) N-acetyl-5-methoxytryptamine Pineal indole diurnal secretion variation widely available as food supplement in North America unlicensed for children & young people in U.K. - only prescribable on named patient basis
  12. 12. Tryptophan Serotonin N-acetylserotonin Melatonin (N-acetyl-5-methoxytryptamine) Tryptophan Serotonin N-acetylserotonin Melatonin (N-acetyl-5-methoxytryptamine)
  13. 13. JAN ET AL 1994:JAN ET AL 1994: 15 children, most with multiple15 children, most with multiple neurological disabilitiesneurological disabilities improved sleepimproved sleep ““significant health, behavioural & socialsignificant health, behavioural & social benefits”benefits” BUTBUT responses not always completeresponses not always complete responses varied considerably depending onresponses varied considerably depending on type of sleep disturbancetype of sleep disturbance not double-blindnot double-blind
  14. 14. JAN & ESPEZEL 1995:JAN & ESPEZEL 1995: Subsequent reportSubsequent report full or partial correction of sleep-wake cyclefull or partial correction of sleep-wake cycle disturbance in almost 90 children with adisturbance in almost 90 children with a range of developmental disabilities,range of developmental disabilities, neurological disorders & chromosomalneurological disorders & chromosomal anomaliesanomalies continuing strict environmental sleepcontinuing strict environmental sleep structuring importantstructuring important side effects & tolerance not notedside effects & tolerance not noted
  15. 15. MELATONIN IN SPECIFICMELATONIN IN SPECIFIC GENETIC DISORDERS:GENETIC DISORDERS: O’Callaghan et al. 1999:O’Callaghan et al. 1999: 7 individuals with7 individuals with tuberous sclerosistuberous sclerosis andand severe sleep problemssevere sleep problems small but significant improvement in total sleepsmall but significant improvement in total sleep timetime non-significant improvement in sleep onsetnon-significant improvement in sleep onset timetime ? Responders & non-responders? Responders & non-responders McArthur & Budden 1998:McArthur & Budden 1998: improved sleep-onset latency, total sleep timeimproved sleep-onset latency, total sleep time & sleep efficiency in 9 individuals with& sleep efficiency in 9 individuals with RettRett syndromesyndrome
  16. 16. Gringras et al., 2012Gringras et al., 2012  Randomised double masked placebo controlled trial for sleep problems in children with neurodevelopmental disabilities  146 children aged 3-16  Total sleep time  by 22.4 minutes  Sleep onset latency  by 37.5 minutes  Melatonin  earlier waking times than placebo  Children fell asleep significantly faster  But woke earlier  And gained little additional sleep on melatonin  Child behaviour & family functioning outcomes favoured melatonin but were not significant  But parents loved it!
  17. 17. Melatonin is:Melatonin is:  Highly beneficial, short-term, rapid-onset & safe treatment for intractable sleep disturbance  Therapeutic dose not predicted by: – severity of sleep disturbance – severity of intellectual disability – presence/absence of autism  Habituation common but not universal  Concomitant psychological, behavioural, educational, family & social interventions essential  No obvious short-term adverse effects but long-term safety has not been confirmed  No adverse effects other than habituation up to 5 years after commencement  Modified-release version (Circadin) probably no better than immediate- release – but cheaper!
  18. 18. Other Options:Other Options: α-2A noradrenergic receptor agonists – Clonidine, Guanfacine – Lack appetite and sleep disturbance – Good for tic disorders – But sedation & ↓ blood pressure Tricyclic antidepressants – Imipramine, Amitriptyline – Good for anxiety, depression, enuresis, tics, insomnia – May need to do ECG ? Calming SSRIs – as above
  19. 19. ClonidineClonidine (Ingrassia & Turk, 2005) α2A noradrenergic receptor agonist Shown efficacy for anxiety, overactivity, impulsiveness, inattentiveness Mildly sedating, mildly hypnotic Good for tics & Tourette’s Good for repeated night time waking No effect on appetite Can drop your blood pressure 25-300 μg daily in divided doses
  20. 20. Acebutolol:Acebutolol: selective beta-1 adrenergic agonist De Leersnyder et al (2003) melatonin antagonist nine children with Smith-Magenis syndrome severe and intractable sleep difficulties successful suppression of inappropriately high morning melatonin levels improved behaviour and concentration, a reduction in delays in sleep onset, increased sleep duration and delayed waking Suggestion of usefulness in Prader-Willi syndrome – but exclude sleep apnoea first!
  21. 21. Puttaswamaiah & Turk (2015)Puttaswamaiah & Turk (2015) Prader-Willi Syndrome & dysfunctional sleep- wake cycle Asleep mid-afternoon on return from school Awake early night and thereafter No response to behavioural approaches No response to evening melatonin Striking, rapid improvements with mid- afternoon acebutolol
  22. 22. AnxietyAnxiety SSRIs especially mildly calming & sedating ones e.g. sertraline, citalopram Beta blockers e.g. propranolol Alpha agonists e.g. clonidine In extremis, low-dose short-term risperidone – can commence as low as 0.125mg twice daily
  23. 23. Anticonvulsant Mood & BehaviourAnticonvulsant Mood & Behaviour Stabilisers:Stabilisers: Carbamazepine, sodium valproate, lamotrigine Excellent anticonvulsants with good safety profiles Beneficial in bipolar/cyclical mood disorders Emerging evidence base for child & adolescent fluctuating mood disorders Now used increasingly for cyclical (and not so cyclical) mood and behaviour challenges in children & young people with complex, multiple & severe developmental disabilities Balancing mood & behaviour can enhance sleep.
  24. 24. Clinical GuidelinesClinical Guidelines Always commence with sleep hygiene measures & behavioural approaches Sleep induction: melatonin Sleep maintenance: clonidine Early morning waking (especially in association with anxiety or mood disorder: sedating SSRI In extremis, low-dose short-term risperidone – can commence as low as 0.125mg
  25. 25. Knowledge Database To Exit Full Screen and Return to the Knowledge Database Press Esc